These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12616737)

  • 21. The effect of depression on motor function and disease severity of Parkinson's disease.
    Papapetropoulos S; Ellul J; Argyriou AA; Chroni E; Lekka NP
    Clin Neurol Neurosurg; 2006 Jul; 108(5):465-9. PubMed ID: 16150537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depression in Parkinson's disease.
    Rihmer Z; Gonda X; Döme P
    Ideggyogy Sz; 2014 Jul; 67(7-8):229-36. PubMed ID: 25509363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anxiety disorders in Parkinson's disease: prevalence and risk factors.
    Dissanayaka NN; Sellbach A; Matheson S; O'Sullivan JD; Silburn PA; Byrne GJ; Marsh R; Mellick GD
    Mov Disord; 2010 May; 25(7):838-45. PubMed ID: 20461800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations].
    Morselli PL; Rizzo M; Tognoni G
    Recenti Prog Med; 1970 Feb; 48(2):97-124. PubMed ID: 5467589
    [No Abstract]   [Full Text] [Related]  

  • 25. [Urinary excretion of the catecholamines adrenaline, noradrenaline and dopamine as well as the derivatives metanephrine and normetanephrine in heart disease patients].
    Mäurer W; Yoshida Y; Kübler W
    Z Kardiol; 1976 Dec; 65(12):1124-38. PubMed ID: 1014804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anxiety, depression, and quality of life in Parkinson's disease.
    Quelhas R; Costa M
    J Neuropsychiatry Clin Neurosci; 2009; 21(4):413-9. PubMed ID: 19996250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive-behavioral therapy for patients with Parkinson's disease and comorbid major depressive disorder.
    Farabaugh A; Locascio JJ; Yap L; Growdon J; Fava M; Crawford C; Matthews J; McCutchen J; Buchin J; Pava J; Alpert JE
    Psychosomatics; 2010; 51(2):124-9. PubMed ID: 20332287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.
    Pintor L; Baillès E; Valldeoriola F; Tolosa E; Martí MJ; de Pablo J
    Gen Hosp Psychiatry; 2006; 28(1):59-64. PubMed ID: 16377367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral and cognitive signs: delineating the significance of impaired catecholamine metabolism in Parkinson's disease progression.
    Salvatore MF; Disbrow EA; Emborg ME
    J Neurochem; 2014 Oct; 131(2):129-33. PubMed ID: 25039428
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients.
    Phu AL; Xu Z; Brakoulias V; Mahant N; Fung VS; Moore GD; Martin A; Starcevic V; Krause M
    J Clin Neurosci; 2014 Jan; 21(1):63-6. PubMed ID: 24035421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Young- versus older-onset Parkinson's disease: impact of disease and psychosocial consequences.
    Schrag A; Hovris A; Morley D; Quinn N; Jahanshahi M
    Mov Disord; 2003 Nov; 18(11):1250-6. PubMed ID: 14639664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Catecholamine concentration and metabolism in old age].
    Frol'kis VV; Bogatskaia LN; Verkhratskiĭ NS; Voronkov GS
    Probl Endokrinol (Mosk); 1975; 21(2):32-8. PubMed ID: 1168905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catecholamines in CSF, plasma, and tissue after autologous transplantation of adrenal medulla to the brain in patients with Parkinson's disease.
    Tyce GM; Ahlskog JE; Carmichael SW; Chritton SL; Stoddard SL; van Heerden JA; Yaksh TL; Kelly PJ
    J Lab Clin Med; 1989 Aug; 114(2):185-92. PubMed ID: 2754305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validity of the 30-item geriatric depression scale in patients with Parkinson's disease.
    McDonald WM; Holtzheimer PE; Haber M; Vitek JL; McWhorter K; Delong M
    Mov Disord; 2006 Oct; 21(10):1618-22. PubMed ID: 16817205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of catecholamines in the biochemical mechanisms of the pathogenesis of hepatocerebral dystrophy].
    Barkhatova VP
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(7):78-84. PubMed ID: 7124230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.
    Chan-Palay V; Asan E
    J Comp Neurol; 1989 Sep; 287(3):373-92. PubMed ID: 2570794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of depression in idiopathic Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S112-9. PubMed ID: 12211151
    [No Abstract]   [Full Text] [Related]  

  • 40. [Dementia and cognitive impairment in Parkinson disease].
    Gershanik OS
    Vertex; 2002; 13(49):184-8. PubMed ID: 12404019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.